Understanding a potentially new therapeutic target in incurable childhood acute lymphoblastic leukaemia
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
Search
Advance testing efficacy of albendazole in childhood acute myeloid leukaemia
Investigating the preclinical efficacy of albendazole in paediatric acute myeloid leukaemia
How does T-cell acute lymphoblastic leukaemia go to the brain?
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Enhancing immunotherapy for the treatment of paediatric brain tumours
Enhancing CAR T-cell expansion and prolonged persistence for the effective treatment of paediatric medulloblastoma
Developing personalised treatments for brain-directed chemotherapy in childhood acute lymphoblastic leukaemia
ALLTogether1 CSF-FLOW Study
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
A molecular approach to predict recurrence or spread of cancer that will lead to improving outcomes for children with rhabdomyosarcoma
MG-fnRMS and CINSARC gene expression signatures to predict relapse in fusion gene negative rhabdomyosarcomas: assessing an approach to improve patient outcomes
Identifying the genetic changes in T-cell acute lymphoblastic leukaemia that fails to respond to chemotherapy
Deciphering the genomic landscape of childhood refractory t-cell acute lymphoblastic leukaemia
Treatment
The treatment your child has will depend on the type of cancer they have.
What is helpful and what is unhelpful about remotely delivered acceptance and commitment therapy for young brain tumour survivors?
What helps and what hinders in remotely delivered acceptance and commitment therapy for survivors of childhood brain tumours: a diary and interview study.